Return to Listing

10 result(s) for

PI Name Protocol # Title
Richard Maziarz STUDY00018449 A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible, Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
Rachel Cook STUDY00019339 Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) therapy and control sub groups: combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in Older Patients (≥ 50 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Richard Maziarz STUDY00019760 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
Lara Davis STUDY00020087 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Evan Shereck STUDY00020192 (BCH IRB) Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT)
Richard Maziarz STUDY00020759 A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma
Richard Maziarz STUDY00021119 An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies
Levanto Schachter STUDY00021454 Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.
Arpita Gandhi STUDY00021456 A Phase 1/2 Study to Evaluate the Safety and Efficacy of JSP191 in Combination with a Reduced Intensity Conditioning Regimen of Low Dose Radiation and Fludarabine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Jennifer Saultz STUDY00021983 A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080